YungShin Global Holding Corporation (TPE:3705)
Taiwan
· Delayed Price · Currency is TWD 68.20
-0.60 (-0.87%)
May 9, 2025, 2:38 PM CST
YungShin Global Holding Revenue
YungShin Global Holding had revenue of 2.18B TWD in the quarter ending March 31, 2025, with 21.30% growth. This brings the company's revenue in the last twelve months to 8.41B, up 17.63% year-over-year. In the year 2024, YungShin Global Holding had annual revenue of 8.03B with 14.29% growth.
Revenue (ttm)
8.41B
Revenue Growth
+17.63%
P/S Ratio
2.16
Revenue / Employee
n/a
Employees
n/a
Market Cap
18.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.03B | 1.00B | 14.29% |
| Dec 31, 2023 | 7.03B | -283.83M | -3.88% |
| Dec 31, 2022 | 7.31B | -493.29M | -6.32% |
| Dec 31, 2021 | 7.81B | -279.61M | -3.46% |
| Dec 31, 2020 | 8.08B | -106.87M | -1.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Pegavision | 6.69B |
| Lumosa Therapeutics | 43.59M |